Russian developer applies for registration of nasal spray coronavirus vaccine
18 March 2022

Russian developer applies for registration of nasal spray coronavirus vaccine

MOSCOW, March 18. /TASS/. Russia’s Gamaleya Center has filed documents with the Health Ministry for the registration of a nasal spray coronavirus vaccine and expects the medication to be registered in the near future, the center’s Director Alexander Gintsburg told TASS on Friday. "Last night, we uploaded everything, the entire report, which is necessary for the registration of the medication. The Health Ministry officially received the documents today. If there is no criticism, we will get a registration certificate based on the results of the phase one and two [trials], as well as permission to release [the vaccine] for public distribution in the near future," he pointed out. Gintsburg also noted that no side effects from the nasal vaccine had been recorded. "There are no side effects, the vaccine contains the same ingredients, the spray nozzle attachment does not require certification so there shouldn’t be any formal objections to registration," he added. In October 2021, the Russian Health Ministry issued a permit for the Gamaleya Center to conduct phase two clinical trials of a nasal spray coronavirus vaccine. Gintsburg said that the nasal spray vaccine, capable of creating an extra barrier to prevent the transmission of the virus, would be an addition to the regular vaccine injections. Read more